Head

Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
Thursday, March 28, 2024
Research, HNC, Symantec Endpoint Protection, Head, Type, Manganese, Chronic kidney disease, Incidence, ASN, CKD, New Drug Application, LAPC, Patient, Layoff, CRL, NDA, Cancer, Galera, Workforce, Pancreatic cancer, Clinical trial, Cisplatin, Society, Therapy, GRECO, File, Food, SOM, FDA, PDUFA, Pharmaceutical industry

We are continuing to explore strategic options to maximize value to our shareholders, including a potential development path for avasopasem.

Key Points: 
  • We are continuing to explore strategic options to maximize value to our shareholders, including a potential development path for avasopasem.
  • The Prescription Drug User Fee Act (PDUFA) target date assigned by the FDA for the NDA was August 9, 2023.
  • Research and development expenses were $3.2 million in the fourth quarter of 2023, compared to $8.1 million for the same period in 2022.
  • General and administrative expenses were $2.0 million in the fourth quarter of 2023, compared to $5.0 million for the same period in 2022.

Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

Retrieved on: 
Thursday, March 28, 2024
AbbVie, Inflammation, Growth, AstraZeneca, Astex Pharmaceuticals, Trinity College, Novartis, Patient, Research, Standard of care, University, Head, Trinity College Dublin, Therapy, Cancer, Drug development, Amgen, Marketing, Pharmaceutical industry

Gallagher is the sixth director to join our board of directors in the past twelve months as we continue to refresh and strengthen the Board governance and oversight required for the next stage of the Company’s development and growth,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.

Key Points: 
  • Gallagher is the sixth director to join our board of directors in the past twelve months as we continue to refresh and strengthen the Board governance and oversight required for the next stage of the Company’s development and growth,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.
  • Dr. Gallagher has directly led or overseen multiple medical product approvals globally, including biologics and small molecules, across several therapeutic areas.
  • Before joining Syndax Pharmaceuticals in 2023, Dr. Gallagher was Head of Development and Chief Medical Officer of AbbVie.
  • Dr. Gallagher was also appointed to serve as a member of the research and development committee of the board of directors.

GCM Grosvenor Expands Credit Team with Two New Hires

Retrieved on: 
Thursday, March 28, 2024
RMBS, CLO, Structuring, Knowledge, Blue, Head, Risk assessment, Investment, CDO, GCM, GCMG, GCM Grosvenor, The Carlyle Group, Financial services

These strategic hires underscore GCM Grosvenor's commitment to providing world class credit investment solutions.

Key Points: 
  • These strategic hires underscore GCM Grosvenor's commitment to providing world class credit investment solutions.
  • GCM Grosvenor's credit team leverages its extensive expertise to invest across the entire credit liquidity spectrum in direct, fund, co-investment and secondary investments.
  • Before joining GCM Grosvenor, Ingles held senior positions at The Carlyle Group and PointState Capital, where he managed credit portfolios across various sectors.
  • "GCM Grosvenor is delighted to welcome Brandon Cahill and Scott Ingles to our credit team," said Fred Pollock, Chief Investment Officer of GCM Grosvenor.

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

Retrieved on: 
Wednesday, March 27, 2024
Research, NCI, AON, Development, Sarcoma, Disease, Neuroblastoma, Shareholder, Patient, CNS, Fast Track, Cash, SBIR, NDA, Syndrome, Cancer, MRR, CLR, BNS, University, Head, External beam radiotherapy, Cure, Wisconsin Alumni Research Foundation, WAM, HERE, Completeness, Safety, Tat, Intellectual property, Patent, PLE, WARF, Symantec Endpoint Protection, Tranche, UW, Pharmaceutical industry

FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.
  • Net cash used in operating activities during the twelve months ended December 31, 2023, was approximately $32.4 million.
  • General and Administrative Expense: G&A expense for the year ended December 31, 2023, was $10.7 million, compared to $9.6 million for the year ended December 31, 2022.
  • Cellectar management will host a conference call for investors today, March 14, 2024, beginning at 8:30 am Eastern Time to discuss these results and answer questions.

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 27, 2024
Principal, PDSB, NCI, Head, Survival, Associate, Incidence, Patient, National Cancer Institute, Cancer, Doctor of Philosophy, Biotechnology, Overalls, Oncology, Neck, ICI, Clinical trial, Immune system, IL-12, ICIS, FDA, Physician, PDS, Food, Pharmaceutical industry

This decision enables PDS Biotech to focus its resources on the drug regimen it believes has the highest potential to benefit patients with HNSCC and to drive shareholder value.

Key Points: 
  • This decision enables PDS Biotech to focus its resources on the drug regimen it believes has the highest potential to benefit patients with HNSCC and to drive shareholder value.
  • “We have had several discussions with key opinion leaders in HNSCC regarding the use of the triple combination in HNSCC.
  • The NCI clinical trial data show significant promise in the use of PDS01ADC in combination with Versamune® HPV,” said Katharine A.
  • The event will be archived on the Investor Relations section of PDS Biotech’s website for six months.

HR Community Readies for Next Month’s EPIC Conference in Las Vegas

Retrieved on: 
Wednesday, March 27, 2024
HR, Culture, Organization, Conference, Hearing, Learning, Business, PALM, Head, Employment, Research, Science, IBM, Courage, Senior, Generation Z, Workforce, EPIC, Workweek and weekend, Social change, Gen, Management

WEST PALM BEACH, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- In only a few short weeks, the HR community will come together for the inaugural Elevate People, Ignite Change (EPIC) Conference taking place at the Bellagio in Las Vegas, April 24 – 26, 2024.

Key Points: 
  • WEST PALM BEACH, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- In only a few short weeks, the HR community will come together for the inaugural Elevate People, Ignite Change (EPIC) Conference taking place at the Bellagio in Las Vegas, April 24 – 26, 2024.
  • “Fostering Gen Z Engagement: Balancing Identity, Advocacy and HR for Business Success” – Set to comprise 30 percent of the workforce by 2030, Gen Z is the most disengaged generation at work today.
  • In a world redefined by generational shifts, technological advancement, social change and the rising cost of living, EPIC bravely confronts the challenges that employees and HR leaders alike are facing head-on.
  • To be part of this EPIC event, register now by visiting https://www.epichr.com/register .

Cabeau Launches Evolution Kids, A Revolutionary Supportive Travel Accessory for Little Ones

Retrieved on: 
Wednesday, March 27, 2024
Neck pain, Life, Head, Sleep, RPET, Travel, Catalog, Toy

The new Evolution Kids neck pillow integrates Cabeau’s signature and award-winning features, including raised side supports and thin, flat back design to prevent the dreaded bobblehead and neck pain.

Key Points: 
  • The new Evolution Kids neck pillow integrates Cabeau’s signature and award-winning features, including raised side supports and thin, flat back design to prevent the dreaded bobblehead and neck pain.
  • The same premium supportive features beloved by adult travelers can now be enjoyed by little ones as well - all in a kid-friendly design.
  • “As Cabeau expands its product catalog with travel comfort for little ones, we continue to innovate in stagnant categories,” said David Sternlight, Founder and Chief Executive Officer of Cabeau.
  • The Evolution Kids joins Cabeau’s collection of award-winning travel pillows including The Neck’s Evolution S3, Evolution Earth, Evolution S3, Air TNE, Evolution Cool, and Evolution Classic.

Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025

Retrieved on: 
Wednesday, March 27, 2024
MSD, Research, Conference call, Conference, Head, AstraZeneca, E7, Patient, Merck & Co., Tumor microenvironment, Merck, News, R&I, Cancer, Virus, MD, E6, Lung cancer, AACR, NEC, European Journal, HPV16, Euronext Paris, De novo, Immune system, ASCO, Safety, Poster, Potyvirus, Pharmaceutical industry

Extended financial visibility secured until Q4 2025 through a revised credit facility provided by the major shareholder Institut Mérieux.

Key Points: 
  • Extended financial visibility secured until Q4 2025 through a revised credit facility provided by the major shareholder Institut Mérieux.
  • “During 2023 Transgene continued to make significant progress, delivering compelling data that confirm the value of our approach to treating cancer using our novel immunotherapies” commented Dr. Alessandro Riva, MD, Chairman and CEO of Transgene.
  • As announced on May 5, 2023, AstraZeneca terminated its oncolytic virus research and development collaboration with Transgene following a strategic review of its pipeline.
  • In 2024, Transgene expects to communicate progress and significant results and readout on all of its clinical stage assets.

Yoshinoya and Botrista Double Down on Boba Tea With New Flavors, Sizes & Ingredients

Retrieved on: 
Tuesday, March 26, 2024
Head, Tax, Tea, Michelin, Promo, Partnership, Social media, FREE, REGULAR, HERE, Restaurant, Boba, CMO, IOS, Android

In partnership with Botrista , a pioneer in the world of beverage-making, Yoshinoya began testing Boba Tea in select restaurants in late 2022.

Key Points: 
  • In partnership with Botrista , a pioneer in the world of beverage-making, Yoshinoya began testing Boba Tea in select restaurants in late 2022.
  • And to celebrate, the brand will be giving away 1 million Boba Teas for FREE during the month of April.
  • As part of Yoshinoya’s Boba menu expansion, starting the first week in April, customers can indulge in a new flavor of Boba Tea, Mango Lemonade.
  • Yoshinoya and Botrista harnessed Michelin-star chef, Rex Huang, in the development of the new flavor of Boba Tea.

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

Retrieved on: 
Tuesday, March 26, 2024
Research, AXL, Head, Congress, NSCLC, SAN, Patient, Webcast, Observation, G&A, Peripheral neuropathy, CAB, Melanoma, D&O, Sarcoma, CD3, AACR, DLT, Conditional, ESMO, SITC, Therapy, ADC, Annual general meeting, SCCHN, Pharmaceutical industry

General and administrative (G&A) expenses were $5.9 million for the quarter ended December 31, 2023 compared to $6.7 million for the same quarter in 2022.

Key Points: 
  • General and administrative (G&A) expenses were $5.9 million for the quarter ended December 31, 2023 compared to $6.7 million for the same quarter in 2022.
  • Net loss for the quarter ended December 31, 2023 was $26.9 million compared to a net loss of $27.6 million for the same quarter in 2022.
  • Cash used for the quarter ended December 31, 2023 was $29.8 million.
  • Cash and cash equivalents as of December 31, 2023 were $111.5 million, compared to $215.5 million as of December 31, 2022.